Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Metastases”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00054574
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Jonsson Comprehensive Cancer Center
Not applicableLooking for participantsNCT06259279
What this trial is testing

High Impact Training to Patients with Prostate Cancer and Bone Metastases

Who this might be right for
Prostate Cancer
Copenhagen University Hospital at Herlev 102
Early research (Phase 1)Ended earlyNCT02429804
What this trial is testing

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Malignant Neoplasm in the BoneMetastatic Prostate Carcinoma
Stanford University 4
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07635524
What this trial is testing

Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

Who this might be right for
Prostate Cancer
Hoag Memorial Hospital Presbyterian 34
Testing effectiveness (Phase 2)WithdrawnNCT01658527
What this trial is testing

TAK-700 in Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Not applicableLooking for participantsNCT07553754
What this trial is testing

Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis

Who this might be right for
Prostate Cancer (Diagnosis)Bone MetastasisPSMA PET+4 more
Xijing Hospital 1,000
Large-scale testing (Phase 3)Study completedNCT03295565
What this trial is testing

Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel

Who this might be right for
Prostate Cancer MetastaticMetastasis
The Netherlands Cancer Institute 100
Early research (Phase 1)Study completedNCT03412786
What this trial is testing

Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases

Who this might be right for
Prostate Cancer
Herlev Hospital 20
Not applicableWithdrawnNCT03043222
What this trial is testing

Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men

Who this might be right for
Lower Urinary Tract SymptomsBenign Prostatic HyperplasiaUrinary Frequency/Urgency+3 more
St. Louis University
Not applicableLooking for participantsNCT06661122
What this trial is testing

Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer 100
Testing effectiveness (Phase 2)Study completedNCT00569153
What this trial is testing

Safety Study of TAK-700 in Subjects With Prostate Cancer.

Who this might be right for
Prostatic Neoplasms
Millennium Pharmaceuticals, Inc. 123
Testing effectiveness (Phase 2)UnknownNCT06001255
What this trial is testing

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Who this might be right for
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Hansoh BioMedical R&D Company 120
Large-scale testing (Phase 3)Active Not RecruitingNCT02051218
What this trial is testing

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Who this might be right for
Metastatic Breast CancerMetastatic Prostate CancerBone Metastases
Swiss Cancer Institute 1,380
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07608718
What this trial is testing

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Pedro Barata, MD, MSc 19
Testing effectiveness (Phase 2)Study completedNCT01934790
What this trial is testing

Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases

Who this might be right for
Prostatic Neoplasms
Bayer 45
Not applicableActive Not RecruitingNCT00578240
What this trial is testing

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 5,290
Early research (Phase 1)Active Not RecruitingNCT04388852
What this trial is testing

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Who this might be right for
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Clear Cell Renal Cell Carcinoma+7 more
M.D. Anderson Cancer Center 65
Testing effectiveness (Phase 2)UnknownNCT03305224
What this trial is testing

The Combination Therapy With Ra-223 and Enzalutamide

Who this might be right for
Castration-resistant Prostate CancerBone Metastases
Taro Iguchi, MD, PHD 10
Not applicableLooking for participantsNCT07221825
What this trial is testing

Low-Count Quantitative SPECT for Men Treated With Radium-223

Who this might be right for
Prostate CancerCancer of the Prostate
Washington University School of Medicine 38
Early research (Phase 1)Study completedNCT01565746
What this trial is testing

Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Who this might be right for
Prostatic Neoplasms
Bayer 19
Next Page